This is an open-label, phase I study to investigate the influence of the bi-daily weekly
dosing of ModraDoc006/ritonavir on the absorption and excretion of docetaxel in patients with
advanced solid tumours.
The pharmacokinetics, absorption and excretion of docetaxel will be investigated during the
study.
Patients will receive 30 mg in the morning / 20 mg in the afternoon ModraDoc006 with BID 100
mg ritonavir in a fasted condition (i.e. at least 1 hour before or 2 hours after any food
assumption), followed by collection of plasma, faeces and urine samples.